05/03/2024: VIS, Inc. launches patient screening for the Opti-K™ Phase IIIa Pivotal Study

05/01/2024: VIS, Inc. releases a US$10MM Private Placement Memorandum (PPM) Class D Preferred Convertible for Accredited investors

04/17/2024: VIS LLC, a Texas Limited Liability Company, converts to VIS, Inc., a Texas C-Corporation

01/01/2024: Cataract & Refractive Surgery Today (CRST) A New Approach to Thermal Keratoplasty

12/20/2023: Health Canada Approves The Opti-K™ Investigational Testing Authorization (ITA) For the Treatment of Dry Age Related Macular Degeneration (AMD)

04/19/23: FDA Approves The Opti-K™ Investigational Device Exemption (IDE) For The Phase III FDA Pivotal Study For the Treatment of Presbyopia

VIS understands that sight is very precious; the one sense people fear losing most. VIS’ mission is to commercialize and scale proprietary, laser-based optical device systems for ophthalmologists to treat patients using, safe, fast, and affordable procedures with excellent results.

DISCLAIMER: The VIS Optimal Keratoplasty (Opti-K™) System is an investigational device, and it is not available for sale or use in the United States.

VIS, Inc.
2800 Dallas Parkway, Suite 100
Plano, TX 75093
United States of America
Monday - Friday 8:00 AM - 6:00 PM
[email protected]
+1 561 819 8300